Effect of Pyrotinib on Levels of Tumor Markers in Patients with HER2-Positive Breast Cancer
Effect of Pyrotinib on Levels of Tumor Markers in Patients with HER2-Positive Breast Cancer
Biao Zhong1*, MengMeng Zou1, Jie Zeng1, Juan Bai2, YongJun Deng3, Xin Li4 and YongQin Wang5
ABSTRACT
Exploring effective treatment regimens for patients with HER2-positive breast cancer (HPBC) is of significant importance. Pyrotinib is a small-molecule tyrosine kinase inhibitor (TKI) developed in China and irreversibly binds to human epidermal growth factor receptor types 1, 2, and 4. The objective of this study was to evaluate the long-term safety and efficacy of Pyrotinib on the carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA15-3), and carbohydrate antigen 125 (CA125) changes in human epidermal growth factor receptor 2 (HER2) positive breast cancer patients. This randomized clinical trial was conducted in China. A total of 50 patients with HPBC, already receiving conventional chemotherapy with trastuzumab combined with docetaxel (TCD), were enrolled in the study, which was conducted from January 2021 to March 2022. Patients were randomly assigned to receive combination therapy with Pyrotinib and TCD (observation group) or TCD chemotherapy (control group) in a 1:1 ratio. Changes in CEA, CA15-3, and CA125 levels at pre-treatment (T0), after 2 treatment cycles (T1), and after 4 treatment cycles (T2), as well as safety parameters of the patients in the 2 groups were compared. The observation group clinical treatment outcomes were significantly higher than those of the control group. However, at T1 and T2, the levels were lower than at T0, with T2 levels being lower than T1 levels. Additionally, at the same time points, the observation group levels were under the control group’s value. No significant difference was identified in the occurrence of adverse reactions between the groups. The integration of Pyrotinib into the treatment regimen for patients with HPBC significantly improves clinical treatment outcomes, prolongs PFS levels, and exhibits an ideal effect in improving tumor markers such as CEA, CA15-3, and CA125 in patients. Moreover, it does not significantly increase the occurrence of adverse reactions while increasing drug usage, thus presenting a relatively ideal treatment safety profile.
To share on other social networks, click on any share button. What are these?
